CHI Advisors’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

CHI Advisors’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-934,135	Closed	-$100M	–	32
2023 Q1	$100M	Buy	934,135 +10,335	+1%	+$1.19M	26.61%	1
2022 Q4	$102M	Sell	923,800 -677,985	-42%	-$44M	27.06%	1
2022 Q3	$94.5M	Sell	1,601,785 -70,191	-4%	-$3.21M	25.42%	1
2022 Q2	$47.2M	Buy	1,671,976 +86,880	+5%	+$2.52M	18.03%	1
2022 Q1	$59.9M	Sell	1,585,096 -167,147	-10%	-$6.61M	25.45%	1
2021 Q4	$69.3M	Sell	1,752,243 -1,109,816	-39%	-$34.7M	23%	1
2021 Q3	$67.9M	Buy	2,862,059 +10,050	+0.4%	+$237K	19.81%	1
2021 Q2	$70M	Sell	2,852,009 -22,023	-0.8%	-$491K	16.29%	2
2021 Q1	$52.5M	Buy	+2,874,032	New	+$59.3M	10.51%	4

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

CHI Advisors's RXDX Position: Q2 2023 in Review

CHI Advisors sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 934,135 shares — an estimated $100M sold.

CHI Advisors first reported a position in RXDX in Q1 2021 and held it in 9 quarters. The position peaked at $102M in Q4 2022. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

CHI Advisors reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
CHI Advisors sold 934,135 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $100M.
CHI Advisors first reported a position in Prometheus Biosciences, Inc. Common Stock in Q1 2021 and held it in 9 quarters.
CHI Advisors's Prometheus Biosciences, Inc. Common Stock position peaked at $102M in Q4 2022.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on CHI Advisors's 13F filing for Q2 2023, filed 11 Aug 2023.